Cookie preferences
We use cookies, including third-party cookies, to collect information about how visitors use our website. The personal data we collect is used to tailor advertisements. Cookies are used to provide you with an optimal browsing experience, to continuously improve our site, and, with your consent, may be used by our partners to display personalised advertising by showing you offers tailored to your interests.

By clicking on the "Accept" button, you consent to the use of all cookies, including those used to personalise advertisements according to your interests. If you close this banner or continuing with essential cookies, only technical and analytical cookies will be used for which your consent is not required. You can revoke your consent to all or some cookies at any time by clicking on the "Cookie Preferences" button, also accessible from the footer of the site.

Detailed information on the use of cookies can be found in our privacy and cookie policy.

DIF1STAT®: A new publication


An integral article entitled: “Effect of combined lipid-lowering and antioxidant nutraceutical on plasma lipids, endothelial function, and estimated cardiovascular disease risk in moderately hypercholesterolemic patients: has recently been published online in the journal, Archives of Medical Science - Atherosclerotic Diseases: a double-blind, placebo-controlled randomized clinical trial ", related to an RCT study conducted by Prof. Arrigo Francesco Giuseppe Cicero, of the Center for the Study of Hypertension and Related Cardiovascular Risk Factors, Department of Medical and Surgical Sciences ( DIMEC), University of Bologna, Bologna, Italy.

This double-blind, placebo-controlled randomized clinical trial aims to evaluate the modulating effect, in a setting of controlled nutritional habits, of a combined food supplement with DIF1STAT (based on red yeast rice with a very low content of monacolins, linear aliphatic alcohols and niacin) and Olea europaea on plasma lipids and endothelial function, in a group of 40 healthy, moderately hypercholesterolemic patients in primary cardiovascular prevention.

The tested nutraceutical association is able to significantly improve different lipid parameters compared to placebo, and endothelial reactivity compared to baseline. Even if the study power appears to be adequate for the primary endpoints, the effect on endothelial function needs confirmation in a longer clinical trial.

https://pubmed.ncbi.nlm.nih.gov/34381916/#affiliation-1
 
pageview